On October 5, 2026, the Utah Department of Commerce announced five new healthcare agreements under its AI regulatory sandbox, including a pilot that allows an AI system to issue initial prescriptions for acne treatment. Together with a prescription renewal pilot approved in October 2025, the agreements show in detail how one state is approaching oversight of AI that takes clinical action, including what the tools may do, how physician review changes over time, and what the state requires before that review is reduced.
A Six-Month Window: DOJ and HHS Offer Defined Terms for Healthcare False Claims Act Self-Disclosures
Posted in Fraud & Abuse & False Claims Act, Government Affairs, Licensure & RegulatoryOne of the hardest questions that healthcare organizations that uncover a potential False Claims Act (FCA) problem have is whether to self-disclose an issue and at what cost. On October 22, 2026, the U.S. Department of Justice (DOJ) Civil Division and the U.S. Department of Health and Human Services (HHS) offered a more concrete answer, at least for a limited time, by launching the Healthcare False Claims Act Self-Disclosure Pilot Program (the FCA SDPP or Pilot).
Less Than Meets the Eye? What DOJ’s Justice Manual Revisions on Sub-Regulatory Guidance and Qui Tam Dismissals Mean for Healthcare Providers
Posted in Fraud & Abuse & False Claims Act, Healthcare LitigationGovernment agency materials, standing alone, can no longer carry a False Claims Act (FCA) case brought by the Department of Justice (DOJ). That is the practical upshot of one of two significant revisions to the Justice Manual announced on September 18, 2026.
Control Was the Question, Continuity Was the Answer: The Eleventh Circuit’s Zafirov Decision Upholds the FCA’s Qui Tam Provisions
Posted in Fraud & Abuse & False Claims Act, Healthcare LitigationWhen the three-judge panel of the Eleventh Circuit Court of Appeals heard oral argument last December, the word repeated through the courtroom was control. On September 1, 2026 the panel handed down a decision in which control plays almost no part at all. In United States ex rel. Zafirov v. Florida Medical Associates, LLC (Zafirov),[1] the appellate court vacated the first-ever district court ruling that the whistleblower (or qui tam) provisions of the federal False Claims Act (FCA) are unconstitutional because they violate the Appointments Clause of the U.S. Constitution. But the court’s opinion did not address whether the executive branch retains sufficient control over relators. Instead, the court concluded that relators never hold anything that looks enough like a continuing office to require an appointment in the first place. So continuity (or the lack thereof), not control, carried the day.
AI-Assisted Data Mining and the False Claims Act: Is a Data Anomaly Really a False Claim?
Posted in Fraud & Abuse & False Claims Act, Healthcare LitigationData miner whistleblowers, increasingly armed with artificial intelligence (AI) tools, are already reshaping how False Claims Act (FCA) theories are built, generated, and litigated. The Department of Justice’s (DOJ) April 2026 announcement of the Fraud Oversight through Careful Use of Statistics (FOCUS) initiative, which will strengthen relationships with data miner relators who have developed “effective tools,” only solidified what the False Claims Act bar had already portended. Not surprisingly, the commentary that followed focused on the public disclosure bar as a notable defense. But what about scienter as a defense? And what does the subjective scienter analysis mean for a relator that is a data miner, an industry outsider whose allegations come from a publicly available dataset, not a seat at any corporate table or a desk down the hall from the allegedly bad actors? In a post-FOCUS world, emphasizing the subjective intent standard will become a critical defense strategy.
Caught by Surprise! NSA’s QPA Calculation Methodology Given the Boot
Posted in Health Insurers & Managed Care Organizations, Health Plans, Healthcare LitigationAfter years of litigation surrounding the No Surprises Act (NSA), there should be no surprise that there are new changes. On August 11, 2026, the Fifth Circuit issued its opinion in Texas Medical Association v. U.S. Department of Health and Human Services, changing how health plans and insurers calculate the Qualifying Payment Amount (QPA) under the NSA. The decision addressed three components of the QPA methodology: “ghost rates,” or rates for items and services that providers don’t actually furnish; bonus and incentive payments; and single-case agreements.
California’s Corporate Practice Crackdown: What Carbon Health, Aspen Dental, and SB 351 Mean for Healthcare Investors and Operators
Posted in Government Affairs, Licensure & Regulatory, Healthcare Law, Healthcare M&A, Joint Ventures, Transactions & Health VenturesCalifornia has long maintained one of the country’s most stringent prohibitions against the corporate practice of licensed professions, including medicine and dentistry. Under that doctrine, only licensed professionals may own and operate their practices. So, to participate in the practice, non-professional investors have historically utilized the so-called “friendly PC” model in which a management services organization (MSO) owned by non-professionals provides administrative, operational, and business management services to a physician- or dentist-owned professional corporation (PC), while the licensed professional serves as its nominal owner.
Georgia Widely Expands Patient Access to More Potent Medical Cannabis but Remains Smokeless
Posted in Government Affairs, Licensure & Regulatory, Pharmacy, Drugs, Medical Devices & Equipment, PhysiciansThe “Putting Georgia’s Patients First Act” (Senate Bill 220 or the Act) brought sweeping changes to the state’s medical cannabis program on July 1, 2026, significantly expanding what had been one of the most restrictive medical cannabis programs in the country for more than a decade. Here’s what it means for the patients the program was designed to serve and the physicians who treat them.
From Biologics to Bandages to Subpoenas: Skin Substitutes Take Center Stage at AHLA
Posted in Fraud & Abuse & False Claims Act, Government Affairs, Licensure & Regulatory, Medicare & MedicaidIn November 2025 we published From Biologics to Bandages, Skin Substitutes Are No Longer the Biologics You Think They Are, flagging an unmistakable shift at the Centers for Medicare & Medicaid Services (CMS) toward constraining a massive increase in government spending on skin substitutes (the biological-based wound coverings used for burns, trauma, and chronic conditions like diabetic ulcers, and referred to by the government in its enforcement actions as “amniotic wound allografts”). As we explained, the cost of skin substitutes to the Medicare program soared from roughly $250 million in 2019 to more than $10 billion by 2024. CMS’s answer was to attack practitioners’ purse strings: as of January 1, 2026, living-cell tissue that once commanded biologic-level reimbursement is now paid under the Physician Fee Schedule as an incident-to supply. Practically speaking, skin substitute reimbursement is now in the same bucket as ordinary office supplies like bandages. CMS projected that change would cut gross fee-for-service spending on skin substitutes by an estimated $19.6 billion in 2026. We predicted that CMS’s growing scrutiny — paired with a June 2025 DOJ announcement of a national enforcement focus, False Claims Act suits, criminal prosecutions, and civil investigative demands — would soon translate into aggressive enforcement. On July 1, 2026, at the American Health Law Association (AHLA) Annual Meeting, senior administration officials made clear that prediction has materialized.
Paper Compliance Versus Economic Reality: Physician Contracting Lessons for Hospitals and Health Systems from a Recent False Claims Act Case
Posted in Fraud & Abuse & False Claims ActA recent False Claims Act (FCA) ruling out of Tennessee offers a pointed reminder for hospitals and health systems: physician contracts that appear compliant on paper can still create serious enforcement risk if the economics tell a different story. In denying motions to dismiss FCA claims involving Erlanger Health System (Erlanger), the federal court allowed allegations regarding physician compensation to proceed, reinforcing that these arrangements remain fertile ground for qui tam relators and the Department of Justice (DOJ). For organizations contracting with physicians, the message is clear: independent fair market value (FMV) review, rigorous documentation, regular auditing, and meaningful board oversight are essential defenses, not mere optional safeguards.